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resolved by 6 weeks in all patients. Our incidence of cellu-
litis was similar to that reported by Cheshire et al9 in their
TriVex group, and we found no difference in either group
of our patients.
There was a higher number of recurrences in the TriVex
group (21.2%; 7 of 33) compared with the conventional
group (6.2%; 2 of 32) at 52 weeks postoperatively. However,
six of these recurrences were in the first 20 TriVex procedures,
which represents our early experience with the technique. We
suggest that a longer familiarization period with the technique
is necessary to obtain results superior to those of conventional
surgery. Data analysis was begun after a learning curve that
included 20 patients, and in hindsight this was insufficient to
learn this new technique.
CONCLUSION
This study shows that TriVex is a safe and effective
method for excision of varicosities. When performed by
trained surgeons it has a comparable complication rate with
that of conventional surgery. It has the advantage of a trend
toward reduced operating time in extensive varicosities,
and results in significantly fewer incisions, although there
was no perceived difference in cosmesis during interval
follow-up. The disposables used for the TriVex procedure
amount to EUR 262 per patient ($314). Despite the
additional cost, we believe that TriVex has a definite place
in treating varicose veins. when time and manpower are
issues.
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DISCUSSION
Dr Peter R. Bell (Leicester, England). I don’t think you really
proved the last statement that you made, where you said powered
phlebectomy was better than the conventional technique. There
was no data to prove that.
Just a few questions. Who did the operations, experienced
surgeons or juniors? Was the study blinded? Did you blind the
assessors who decided on the cosmesis?
All this fluid you gave them, how many attacks of cardiac
failure did you have?
What do you mean by neurapraxia? It’s a huge incidence of
neurapraxia. Where did it occur?
And you forgot one important element, the cost.
Dr Prakash Madhavan. I think we were very clear in the
paper to say that, although there was a trend that TriVex was faster
in patients with extensive varicosities, it did not reach statistical
significance. In addition, in the Conclusion, all we have claimed is
that there appears to be an advantage in using TriVex, especially in
patients with extensive varicosities.
All patients are operated on by an experienced group of senior
registrars and trainees with consultant supervision.
The patients were blinded to the treatment groups. They did
not know what procedure they had undergone until the bandages
were taken off.
There was no incidence of cardiac failure in the TriVex group.
With regard to neurapraxia, this was assessed by asking them a
simple question: “Do you have any tingling or numbness in your
leg?” The figures quoted are in the distribution of the saphenous
and sural nerves. The apparently high incidence of nerve injury at
first follow-up reduced to 3% at 1 year without any major nerve
injuries.
Dr Robert B. McLafferty (Springfield, Ill). I was hoping that
TriVex was going to show better results. I continually struggle
with feeling the pressure to learn all these new technologies pre-
sented in our specialty, and now I realize I don’t need to go out
and learn something new. You have shown that conventional
treatment is as good as TriVex.
A mean of 29 incisions for varicose veins seems awfully high
for the conventional method. I wonder if there was bias in your
study, knowing you were comparing TriVex with conventional
treatment. I don’t think I’d make that many incisions even in a leg
with extensive varicose veins.
Dr Madhavan. Well, this was based on standard techniques
that we use for conventional surgery. We actually validated this
by looking at the number of incisions we used in patients before
the trial. This would be the average number of incisions we
would use for extensive varicose veins. This was based on a
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standard method of phlebectomy; an incision was made with a
30-degree iridectomy knife every 4 to 5 cm along the marked
varicosity.
Now, I think the point to note is that for the average patient
with a few varicosities, you don’t have to use TriVex. But in
patients with extensive varicosities, when you know you’ve got to
throw away the clock and bring in the calendar, I think you’ll reach
for the resector.
Dr Harry Schanzer (New York, NY). I enjoyed very much
this paper. I think that it’s a model of how to evaluate new
technology. The problem that I have is you conclude that it’s a safe
procedure. And I guess that by that you imply that it should be
tried and used. I would like to know why I should try a procedure
that has, at the end, the same results as conventional therapy, with
a cost of equipment of about $30,000.
Dr Madhavan. The cost is certainly a factor to be considered.
In the Irish system we are not able to accurately cost operating
time, unlike in the United States. I gather that operating room
costs are in the region of $25 per minute. If this is the cost, then it
is easy to see how using TriVex may result in cost savings.
I think where TriVex is possibly going to be of great use is not
in the patient with a few varicose veins to be pulled, but when you
have extensive varicosities. We have looked at a subset of patients
outside of the trial with single-surgeon operation, and there is a
significant reduction in operating time when TriVex is used: a
mean of about 18 minutes for grade 1, 30 minutes for grade 2, and
40 minutes for grade 3 varicosities. So I think in patients with
extensive varicosities it certainly is of benefit.
Dr Mark A. Adelman (New York, NY). I’d like you to break
down the cosmetic outcomes to some extent, if you could. I think
with the conventional phlebectomy group, likely your cosmetic fail-
ures were due to the large number of incisions. But you didn’t indicate
what your cosmetic failures were in the TriVex group. And in my
personal experience, we’ve had some hematoxylin staining, which has
been a problem, for me at least. Could you comment on that.
Dr Madhavan. Well, when we did our initial feasibility study,
we did not use the high-pressure injector. Since we started using
the injector, we have not seen this kind of pigmentation. We might
have been lucky. And I’m quite sure that as time goes on we might
well pick up a few in further follow-up.
Dr Adelman. So what was the cosmetic failure, then, in the
TriVex group that made it equal to your 29 incisions?
Dr Madhavan. When we looked at the overall numbers, the
patients weren’t overly concerned about the number of incisions,
and perhaps that is one thing that we need to take into account. It
was the patients’ perception of cosmesis that we looked at. Fur-
thermore, the use of an iridectomy knife results in a tiny incision,
which becomes truly invisible in about 6 weeks. So I don’t think
the number of incisions had anything to do with the cosmesis.
Dr Michael C. Dalsing (Indianapolis, Ind). Many of these
new devices are being introduced to decrease operative time and
hopefully to decrease some complication, neurologic deficits being
one of them. How did you determine the nerve injuries experi-
enced during this study, by extensive neurologic evaluation or just
a questionnaire? Certainly the method of evaluation will affect your
findings and our interpretation of your results.
Dr Madhavan. The assessment of nerve injuries was based on
asking all patients a simple question at 1, 2, 6 weeks and at 1 year.
No extensive neurologic evaluation was attempted. If a patient
complained of paresthesia in either the saphenous or sural nerve
distributions, this was confirmed by a clinical examination to assess
whether this was indeed the case.
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